Skip to main
KYTX
KYTX logo

KYTX Stock Forecast & Price Target

KYTX Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kyverna Therapeutics Inc. is seeing increased confidence in its lead product, KYV-101, particularly regarding its applicability in the treatment of myasthenia gravis (MG) and potentially beyond, supported by expert insights. The company's probability of regulatory approval for KYV-101 has been raised, reflecting stronger expectations for the product's durability and efficacy demonstrated in compassionate-use cases, along with positive indications in refractory rheumatoid arthritis (RA) and early signals in multiple sclerosis (MS). Additionally, recent data support KYV-101's competitive position in the market, indicating its potential to outperform existing therapies, thereby enhancing the company's long-term growth prospects.

Bears say

Kyverna Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to the lack of durable responses observed in patients treated with its lead product candidate, KYV-101, in lupus nephritis (LN) and myasthenia gravis (MG). Additionally, the potential failure to generate positive data for KYV-101 in stiff person syndrome (SPS) raises concerns about the viability of its key products. Furthermore, the threat of long-term dilution risk adds an additional layer of uncertainty regarding the company's financial health and future performance.

KYTX has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kyverna Therapeutics Inc (KYTX) Forecast

Analysts have given KYTX a Buy based on their latest research and market trends.

According to 3 analysts, KYTX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kyverna Therapeutics Inc (KYTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.